MELA, Flora
 Distribuzione geografica
Continente #
NA - Nord America 1.489
EU - Europa 332
AS - Asia 247
OC - Oceania 1
SA - Sud America 1
Totale 2.070
Nazione #
US - Stati Uniti d'America 1.473
CN - Cina 142
UA - Ucraina 110
TR - Turchia 74
DE - Germania 72
GB - Regno Unito 59
IT - Italia 37
SG - Singapore 24
FI - Finlandia 22
SE - Svezia 19
CA - Canada 15
FR - Francia 5
CZ - Repubblica Ceca 3
IN - India 3
BE - Belgio 2
HK - Hong Kong 2
AU - Australia 1
CL - Cile 1
CR - Costa Rica 1
IE - Irlanda 1
IR - Iran 1
KH - Cambogia 1
NL - Olanda 1
RO - Romania 1
Totale 2.070
Città #
Woodbridge 225
Fairfield 216
Chandler 123
Jacksonville 121
Houston 119
Ashburn 112
Wilmington 82
Seattle 75
Cambridge 66
Ann Arbor 48
Beijing 47
Izmir 46
Nanjing 30
Princeton 23
Shanghai 23
Ferrara 20
New York 20
Munich 18
San Diego 16
Boardman 15
Singapore 15
Bremen 13
Mcallen 13
Hebei 12
Montréal 12
Shenyang 9
Washington 8
Milan 6
Changsha 5
Mountain View 5
Jiaxing 4
San Mateo 4
Augusta 3
Brno 3
Dearborn 3
Guangzhou 3
Leawood 3
Nanchang 3
Norwalk 3
Redwood City 3
Verona 3
Aurora 2
Bangalore 2
Brussels 2
Delianuova 2
Hong Kong 2
Indiana 2
Los Angeles 2
Orange 2
Tianjin 2
Ardabil 1
Brisbane 1
Chicago 1
Chiswick 1
Coyhaique 1
East Peoria 1
Edmonton 1
Fuzhou 1
Gainesville 1
Hangzhou 1
Helsinki 1
Heredia 1
Kilburn 1
Kunming 1
Limerick 1
London 1
Monmouth Junction 1
Phnom Penh 1
Pisa 1
Porto Torres 1
Pune 1
Redmond 1
Secaucus 1
Southwark 1
Springfield 1
Stockholm 1
Zhengzhou 1
Totale 1.623
Nome #
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 157
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats 136
Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111 121
Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex 118
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels 118
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior 115
Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease 113
Striatal Dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors 107
Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors 107
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease 106
Changes of glutamatergic control of striatal acetylcholine release in experimental parkinsonism 105
Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington’s disease 105
Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex. 102
The selective D3 receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats 88
null 82
Differential role of striatal and nigral D1receptors in the expression of L-DOPA induced dyskinesia and its neurochemical correlates 82
Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release 76
Nociceptin/orphanin FQ receptor antagonists riverse akinesia in rat parkinsonian models 61
L-DOPA-induced modulation of GABA and glutamate release in the substantia nigra pars reticulata and globus pallidus in a rat model of dyskinesia 61
Nociceptin/orphanin FQ receptor antagonists as a novel therapeutic approach to Parkinson’s disease: interaction with levodopa 59
Novel therapeutic strategies for treatment of motor abnormalities in Parkinson’s disease: focus on opioid receptors 56
Group-II metabotropic glutamate receptors negatively modulate NMDA transmission at striatal cholinergic terminals: role of P/Q-type high voltage activated Ca++ channels and endogenous dopamine 10
Totale 2.085
Categoria #
all - tutte 7.738
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 364
Totale 8.102


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020520 74 21 15 69 35 57 37 58 43 45 53 13
2020/2021301 29 29 15 34 16 36 10 33 8 31 43 17
2021/2022232 8 32 25 1 16 6 14 5 9 19 23 74
2022/2023248 24 27 14 25 49 34 6 17 40 1 8 3
2023/2024147 9 14 8 3 13 34 7 15 8 3 2 31
2024/20254 4 0 0 0 0 0 0 0 0 0 0 0
Totale 2.085